New combo attack on prostate cancer shows promise in early trial
Disease control
Ongoing
This phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…
Phase: PHASE2 • Sponsor: Xiao X. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC